Aibotics, Inc. (AIBT)

Executive Summary

Aibotics, Inc. (formerly Mycotopia Therapies, Inc.; SEC filings still use the legacy ticker/CIK reference "TPIA") is a Miami, Florida-based micro-cap company that pivoted in late 2024 from psychedelic-medicine research toward AI-enabled consumer wellness robotics, while retaining a residual psychedelic-research relationship. The company is extremely small — 2025 revenue of just $2,183, a $2.2 million net loss, and an undisclosed but minimal headcount — and trades on OTC Markets as a sub-penny stock (around $0.0005/share, market cap roughly $329,000 as of August 2026). It is a speculative, pre-commercial company rather than an established operating business.

Core Business Model & How They Work

Aibotics does not yet have a functioning revenue-generating business; its 2025 filings show negligible sales. The company's strategy is to commercialize two AI-enabled consumer hardware products — an AI massage robot ("Phill") and a smart breast-milk storage refrigerator ("Milkyway") — acquired from Philon Labs in November 2024 via an asset-purchase agreement paid largely in $2 million of convertible preferred stock rather than cash. In parallel, it maintains a supply agreement with Havn Life Sciences for naturally derived psilocybin, a holdover from its former identity as psychedelic-therapy developer Mycotopia Therapies, though this legacy line is no longer the company's stated strategic focus.

Business Segments

Aibotics does not report distinct financial segments; it is a single small enterprise with two nascent product lines (AI consumer robotics) plus a legacy psychedelic-research supply relationship that has not been discontinued but is not a meaningful revenue contributor.

Product Portfolio

• Phill Robot — an AI-controlled personal massage device (35-inch range, 15-pound massage force) using adaptive algorithms marketed as a "world's first AI massage robot."
• Milkyway — a smart refrigerator for breast-milk storage with automated organization and temperature monitoring.
• Psilocybin research supply — a continuing but non-core arrangement with Havn Life Sciences supporting psychedelic-compound research.

Competitive Landscape

In consumer massage/wellness devices, Aibotics would compete against far larger, well-capitalized players such as Theragun (Therabody), Hyperice, and mainstream massage-chair manufacturers, none of which it can currently match on distribution, brand recognition, or R&D budget. In smart baby/infant-care hardware, it would face competitors like Willow and Elvie (breast pumps/storage tech) and other connected nursery-device makers. Aibotics has essentially no market share or brand presence in either category yet, and its prior identity in psychedelic therapeutics placed it against a different, better-funded set of clinical-stage biotech competitors (e.g., Compass Pathways, MindMed) that it has now largely exited.

Strategic Strengths & Risks

Strengths: low-cost asset acquisition (products obtained via stock rather than large cash outlay), differentiated novelty positioning ("first AI massage robot") that can generate press/marketing attention cheaply, and optionality from a captive psychedelic-research supply relationship if that market reheats. Risks: the company is pre-revenue in any meaningful sense ($2,183 in 2025 sales) with a $2.2 million annual net loss and thin cash ($255,940 at year-end 2025) — a going-concern-level cash runway; it has pivoted business models twice in a short period (psychedelics to AI robotics), raising execution-consistency concerns; it trades as a sub-penny OTC stock with heavy share dilution (486.9 million shares outstanding) typical of struggling micro-caps; and it faces no discernible manufacturing, distribution, or IP moat versus established consumer-hardware competitors.

Financial Overview

FY2025: revenue $2,183; net loss $2,215,751; cash on hand $255,940; shares outstanding approximately 486.9 million. As of August 2026 the stock traded near $0.0005/share with a market capitalization of roughly $329,000, and a subsequent 10-Q reportedly showed a deepening quarterly loss alongside going-concern risk language. These figures place Aibotics among the smallest and most speculative names in the "AI" small-cap universe.

Summary Conclusion

Aibotics is a nano-cap, largely pre-revenue company whose AI-robotics pivot is still unproven commercially, with going-concern-level financial fragility and no demonstrated competitive advantage in either the consumer-wellness-device or infant-care-tech categories it has entered. Any investment thesis here is purely speculative on future product execution rather than on current business fundamentals.